HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chattem

This article was originally published in The Rose Sheet

Executive Summary

Sales rose 56% to $146.2 mil. in the fiscal first half (ended May 31). For the three months, sales increased 43% to $83.4 mil., attributed in part to the Ban antiperspirant and deodorant brand. Gold Bond also had a "strong performance" during the period, driven by the "continuing strength" of its medicated lotion. Net income in the half was up 136% to $10.5 mil., prior to an extraordinary loss and product divestiture. Through three months, net income rose 87% to $6.9 mil. Chattem recorded a loss of $1.9 mil. on the early extinguishment of debt

Latest Headlines
See All
UsernamePublicRestriction

Register

RS006855

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel